12,791 Shares in PROCEPT BioRobotics Co. (NASDAQ:PRCT) Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky purchased a new position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 12,791 shares of the company's stock, valued at approximately $1,030,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC grew its holdings in shares of PROCEPT BioRobotics by 11.9% during the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Vanguard Group Inc. increased its stake in PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after acquiring an additional 297,075 shares during the period. Alliancebernstein L.P. raised its position in PROCEPT BioRobotics by 14.2% in the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock worth $141,110,000 after purchasing an additional 218,148 shares in the last quarter. Wellington Management Group LLP boosted its holdings in PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock valued at $120,051,000 after purchasing an additional 416,819 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock valued at $93,751,000 after purchasing an additional 57,449 shares during the period. Institutional investors and hedge funds own 89.46% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PRCT shares. Bank of America cut their price target on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Friday, April 25th. Morgan Stanley dropped their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, Truist Financial reduced their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $90.00.

Insider Activity

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock valued at $368,322 over the last ninety days. 17.40% of the stock is currently owned by company insiders.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock traded up $2.77 during trading on Friday, hitting $55.62. 930,808 shares of the stock were exchanged, compared to its average volume of 805,885. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average price of $56.75 and a 200-day moving average price of $73.36. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -28.52 and a beta of 1.09. PROCEPT BioRobotics Co. has a 1-year low of $47.04 and a 1-year high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $69.16 million during the quarter, compared to analysts' expectations of $65.39 million. During the same period last year, the firm posted ($0.51) earnings per share. The business's revenue was up 55.5% on a year-over-year basis. As a group, equities analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).